MYLI
NBIX icon

Meiji Yasuda Life Insurance’s Neurocrine Biosciences NBIX Stock Holding History

Meiji Yasuda Life Insurance’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949K Buy
5,628
+100
+2% +$14.8K 0.03% 145
2026
Q1 		$728K Hold
5,528
– – 0.02% 161
2025
Q4 		$784K Sell
5,528
-78
-1% -$11.3K 0.02% 150
2025
Q3 		$787K Hold
5,606
– – 0.02% 149
2025
Q2 		$705K Hold
5,606
– – 0.02% 160
2025
Q1 		$620K Sell
5,606
-194
-3% -$24.6K 0.01% 180
2024
Q4 		$792K Hold
5,800
– – 0.01% 162
2024
Q3 		$668K Hold
5,800
– – 0.01% 174
2024
Q2 		$798K Buy
5,800
+2,500
+76% +$343K 0.02% 177
2024
Q1 		$455K Buy
+3,300
New +$451K 0.01% 222

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meiji Yasuda Life Insurance's NBIX Position: Q2 2026 in Review

Meiji Yasuda Life Insurance increased its Neurocrine Biosciences (NBIX) stake by 1.8% in Q2 2026, buying an estimated $14.8K and bringing the position to 5,628 shares worth $949K. The position accounts for 0.03% of the portfolio, ranked #145.

Meiji Yasuda Life Insurance first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Meiji Yasuda Life Insurance held 5,628 shares of Neurocrine Biosciences worth $949K as of Q2 2026.
  • Meiji Yasuda Life Insurance bought 100 Neurocrine Biosciences shares in Q2 2026, an estimated $14.8K.
  • Neurocrine Biosciences made up 0.03% of Meiji Yasuda Life Insurance's portfolio in Q2 2026, its #145 holding.
  • Meiji Yasuda Life Insurance first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Meiji Yasuda Life Insurance's 13F filing for Q2 2026, filed 13 Aug 2026.